Special Issue "Next Generation Sequencing for HIV Drug Resistance Testing"
Deadline for manuscript submissions: closed (31 May 2020).
Interests: HIV drug resistance; treatment monitoring and transmission
Drug resistance remains a global challenge in the fight against the HIV pandemic, as recognized by the World Health Organization and the United Nations. Where feasible, guidelines recommend testing for drug resistance before and during antiretroviral therapy to guide regimen selection. Where less available, such testing is used only in specific populations, and where even less accessible, it is used for public health surveillance. Sanger sequencing, available since the 1970s, has conventionally been used for HIV drug resistance testing in clinical care and research. More recently developed next-generation sequencing (NGS) methods are increasingly used in diverse circumstances, including for HIV drug resistance testing. Whether these technologies can and should replace Sanger sequencing for HIV drug resistance testing is unclear, mostly due to associated financial, infrastructure, and logistical challenges. This topic was recently discussed at the International Symposium on External Quality Assurance Strategies for NGS-based HIV drug resistance testing, convened in Winnipeg, Canada in September 2019. In this Special Issue, I invite Symposium participants to highlight related opportunities and challenges that were discussed in the Symposium. I also invite other experts and interested individuals to contribute to this discussion. Deliberations will emphasize logistical and implementation needs and considerations in incorporation of NGS for HIV drug resistance testing, towards clarifying this existing gap and helping clinical, public health and programmatic resolutions.
Dr. Rami Kantor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- HIV drug resistance
- Next-generation sequencing